The Technical Analyst
Select Language :
Exelixis Inc [EXEL]

Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology

Exelixis Inc Price, Forecast, Insider, Ratings, Fundamentals & Signals

Current Signal: SELL (auto-tracking)

Exelixis Inc is listed at the  Exchange

1.06% $23.86

America/New_York / 27 mar 2024 @ 16:00


FUNDAMENTALS
MarketCap: 7 234.21 mill
EPS: 0.650
P/E: 36.71
Earnings Date: Apr 30, 2024
SharesOutstanding: 303.19 mill
Avg Daily Volume: 2.33 mill
RATING 2024-03-27
S-
Strong Buy
RATINGS
Rating CashFlow: Strong Buy
Return On Equity: Buy
Return On Asset: Strong Buy
DE: Neutral
P/E: Strong Buy
Price To Book: Strong Buy
QUARTER GROWTHS
3/224/221/232/233/234/23
Revenue
Gr.Profit
Ebit
Asset
Debt
PE RATIO: COMPANY / SECTOR
0.00x
Company: PE 36.71 | sector: PE -3.05
PE RATIO: COMPANY / INDUSTRY
6.24x
Company: PE 36.71 | industry: PE 5.88
DISCOUNTED CASH FLOW VALUE
$67.04
(180.96%) $43.18
Date: 2024-03-28
Expected Trading Range (DAY)

$ 23.36 - 24.37

( +/- 2.12%)
ATR Model: 14 days

Insider Trading

Date Person Action Amount type
2024-03-21 Garber Alan M Buy 23 491 Common Stock
2024-03-21 Garber Alan M Sell 19 205 Common Stock
2024-03-21 Garber Alan M Sell 23 491 Option (right to buy)
2024-02-23 Peterson Amy C. Buy 82 121 Common Stock
2024-02-23 Aftab Dana Buy 63 350 Common Stock
INSIDER POWER
27.48
Last 94 transactions
Buy: 3 435 845 | Sell: 2 083 268

Forecast: 16:00 - $23.85

Live Trading Signals (every 1 min)

Forecast 1: 16:00 - $23.85
Forecast 2: 16:00 - $23.85
Forecast 3: 16:00 - $23.85
SCORE
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Indicator Signals
RSI 21
SMA
Trend
Trend 2
Trend 3
MACD
Volume Signals
Price $23.86 (1.06% )
Volume 1.545 mill
Avg. Vol. 2.33 mill
% of Avg. Vol 66.17 %
Signal 1:
Signal 2:

Today

Intraday chart data with high, low, open and close for Exelixis Inc

Last 12 Months

Last 12 months chart data with high, low, open and close for Exelixis Inc

RSI

Intraday RSI14 chart for Exelixis Inc

Last 10 Buy & Sell Signals For EXEL

0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%

Avg return buy: 0.00 % | Avg return sell: 0.00 %

$1 invested is now $1.00 or 0.00% since Coming Soon

Date Signal @ Closed %
Feb 8 - 15:35sell$20.24N/AActive
Profile picture for
            Exelixis Inc

EXEL

Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of patients with progressive and metastatic medullary thyroid cancer. Its CABOMETYX and COMETRIQ are derived from cabozantinib, an inhibitor of multiple tyrosine kinases, including MET, AXL, RET, and VEGF receptors. The company also offers COTELLIC, an inhibitor of MEK as a combination regimen to treat advanced melanoma; and MINNEBRO, an oral non-steroidal selective blocker of the mineralocorticoid receptor for the treatment of hypertension in Japan. In addition, it is developing XL092, an oral tyrosine kinase inhibitor that targets VEGF receptors, MET, AXL, MER, and other kinases implicated in growth and spread of cancer; XB002, an antibody-drug conjugate composed of human mAb against tissue factor (TF) for the treatment of advanced solid tumors; XL102, an orally bioavailable cyclin-dependent kinase 7 (CDK7) inhibitor for the treatment of advanced or metastatic solid tumors; and XB002 for the treatment of non-hodgkin's lymphoma. Exelixis, Inc. has research collaborations and license agreements with Ipsen Pharma SAS; Takeda Pharmaceutical Company Ltd.; F. Hoffmann-La Roche Ltd.; Redwood Bioscience, Inc.; R.P. Scherer Technologies, LLC; Catalent Pharma Solutions, Inc.; NBE Therapeutics AG; Aurigene Discovery Technologies Limited; Iconic Therapeutics, Inc.; Invenra, Inc.; StemSynergy Therapeutics, Inc.; Genentech, Inc.; Bristol-Myers Squibb Company; and Daiichi Sankyo Company, Limited. The company was formerly known as Exelixis Pharmaceuticals, Inc. and changed its name to Exelixis, Inc. in February 2000. Exelixis, Inc. was incorporated in 1994 and is headquartered in Alameda, California.

Last 10 Buy Signals

Date Signal @
DPXUSDMar 28 - 07:3541.79
YAKUSDMar 28 - 07:33839.25
^N100Mar 28 - 07:22PTS1 528.40
RNDRUSDMar 28 - 07:3411.36
XCHUSDMar 28 - 07:31$41.54
^FCHIMar 28 - 07:18PTS8 235.70
PENDLEUSDMar 28 - 07:284.12
KCSUSDMar 28 - 07:19$12.09
DIGGUSDMar 28 - 07:19914.30
ETHXUSDMar 28 - 07:183 584.83

Latest Press Releases

Latest News

Disclaimer:

"JimStromberg.com" is a research service that provides financial data and technical analysis of publicly traded stocks. All users should speak with their financial advisor before buying or selling any securities. Users should not base their investment decision upon "JimStromberg.com". By using the site you agree and are held liable for your own investment decisions and agree to Terms of Use and Privacy Policy. Please read the full disclaimer here.